Chidozie Ugwumba Sells 61,345 Shares of Clene (NASDAQ:CLNN) Stock

Clene Inc. (NASDAQ:CLNN) major shareholder Chidozie Ugwumba sold 61,345 shares of the firm’s stock in a transaction dated Tuesday, April 21st. The shares were sold at an average price of $6.14, for a total transaction of $376,658.30. Following the transaction, the insider owned 297,066 shares of the company’s stock, valued at $1,823,985.24. This trade represents a 17.12% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Major shareholders that own at least 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Chidozie Ugwumba also recently made the following trade(s):

• On Monday, April 20th, Chidozie Ugwumba sold 4,318 shares of Clene stock. The shares were sold at an average price of $6.12, for a total transaction of $26,426.16.
• On Friday, April 17th, Chidozie Ugwumba sold 25,040 shares of Clene stock. The shares were sold at an average price of $6.43, for a total transaction of $161,007.20.
• On Thursday, April 16th, Chidozie Ugwumba sold 7,748 shares of Clene stock. The shares were sold at an average price of $6.40, for a total transaction of $49,587.20.
• On Wednesday, April 15th, Chidozie Ugwumba sold 6,374 shares of Clene stock. The shares were sold at an average price of $6.48, for a total transaction of $41,303.52.
• On Thursday, April 2nd, Chidozie Ugwumba sold 24,925 shares of Clene stock. The shares were sold at an average price of $4.81, for a total transaction of $119,889.25.
• On Wednesday, April 1st, Chidozie Ugwumba sold 4,278 shares of Clene stock. The stock was sold at an average price of $4.97, for a total transaction of $21,261.66.
• On Tuesday, February 3rd, Chidozie Ugwumba sold 5,559 shares of Clene stock. The stock was sold at an average price of $4.10, for a total transaction of $22,791.90.
• On Monday, February 2nd, Chidozie Ugwumba sold 3,800 shares of Clene stock. The stock was sold at an average price of $4.04, for a total transaction of $15,352.00.
• On Friday, January 30th, Chidozie Ugwumba sold 5,686 shares of Clene stock. The stock was sold at an average price of $4.13, for a total transaction of $23,483.18.
• On Thursday, January 29th, Chidozie Ugwumba sold 15,284 shares of Clene stock. The stock was sold at an average price of $4.32, for a total transaction of $66,026.88.

Clene Price Performance

Shares of NASDAQ CLNN opened at $6.15 on Friday. The company has a market cap of $72.45 million, a PE ratio of -2.37 and a beta of 0.62. Clene Inc. has a 12 month low of $2.28 and a 12 month high of $13.50. The company has a 50-day simple moving average of $5.53 and a 200-day simple moving average of $6.62.

Clene (NASDAQ:CLNN) last issued its quarterly earnings results on Thursday, March 12th. The company reported ($0.88) EPS for the quarter, missing analysts’ consensus estimates of ($0.74) by ($0.14). The firm had revenue of $0.08 million for the quarter, compared to analyst estimates of $0.03 million. On average, analysts anticipate that Clene Inc. will post -1.99 EPS for the current year.

Institutional Investors Weigh In On Clene

Hedge funds have recently modified their holdings of the stock. Jones Financial Companies Lllp acquired a new stake in shares of Clene in the third quarter worth approximately $29,000. Jane Street Group LLC acquired a new stake in shares of Clene in the second quarter worth approximately $47,000. State Street Corp boosted its position in shares of Clene by 138.4% in the fourth quarter. State Street Corp now owns 29,801 shares of the company’s stock worth $175,000 after acquiring an additional 17,300 shares during the last quarter. PEAK6 LLC acquired a new stake in shares of Clene in the fourth quarter worth approximately $294,000. Finally, Lunt Capital Management Inc. boosted its position in shares of Clene by 2.5% in the third quarter. Lunt Capital Management Inc. now owns 52,260 shares of the company’s stock worth $315,000 after acquiring an additional 1,250 shares during the last quarter. 23.28% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of brokerages have recently commented on CLNN. Weiss Ratings reiterated a “sell (d-)” rating on shares of Clene in a report on Friday, January 9th. D. Boral Capital reiterated a “buy” rating and set a $23.00 price target on shares of Clene in a report on Thursday, March 12th. Finally, Canaccord Genuity Group reiterated a “buy” rating and set a $48.00 price target on shares of Clene in a report on Friday, March 13th. Four investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Clene has an average rating of “Moderate Buy” and a consensus target price of $34.00.

About Clene

Clene (NASDAQ: CLNN), also known as Clene Nanomedicine, is a clinical-stage biopharmaceutical company developing proprietary nanoparticle therapies aimed at treating neurodegenerative and demyelinating disorders. The company’s flagship product, CNM-Au8, is a suspension of catalytic gold nanocrystals designed to enhance cellular energy metabolism, promote remyelination, and reduce oxidative stress. Clene’s platform leverages the unique physicochemical properties of its nanoparticles to support neuronal health, with a focus on diseases that currently lack effective disease-modifying treatments.

Clene’s lead candidate, CNM-Au8, is undergoing multiple clinical trials targeting conditions such as amyotrophic lateral sclerosis (ALS), Parkinson’s disease, and multiple sclerosis (MS).